Axonics Modulation Technologies (AXNX) – Research Analysts’ Weekly Ratings Updates

Axonics Modulation Technologies (NASDAQ: AXNX) recently received a number of ratings updates from brokerages and research firms:

  • 12/2/2018 – Axonics Modulation Technologies is now covered by analysts at Morgan Stanley. They set an “overweight” rating and a $14.92 price target on the stock.
  • 11/26/2018 – Axonics Modulation Technologies is now covered by analysts at Morgan Stanley. They set an “overweight” rating and a $21.00 price target on the stock.
  • 11/26/2018 – Axonics Modulation Technologies is now covered by analysts at Wells Fargo & Co. They set an “outperform” rating and a $22.00 price target on the stock.
  • 11/26/2018 – Axonics Modulation Technologies is now covered by analysts at SunTrust Banks, Inc.. They set a “buy” rating and a $20.00 price target on the stock.
  • 11/26/2018 – Axonics Modulation Technologies is now covered by analysts at Bank of America Corp. They set a “buy” rating and a $23.00 price target on the stock.

AXNX traded up $0.33 during trading on Wednesday, reaching $14.34. 200,456 shares of the stock traded hands, compared to its average volume of 174,772. Axonics Modulation Technologies Inc has a 12 month low of $11.95 and a 12 month high of $17.00.

In other news, Director Bakker Juliet Tammenoms acquired 533,333 shares of Axonics Modulation Technologies stock in a transaction dated Friday, November 2nd. The stock was purchased at an average cost of $15.00 per share, with a total value of $7,999,995.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Cormorant Asset Management, Lp acquired 133,333 shares of Axonics Modulation Technologies stock in a transaction dated Wednesday, October 31st. The stock was purchased at an average cost of $15.00 per share, with a total value of $1,999,995.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders have acquired 1,533,332 shares of company stock valued at $22,999,980.

Axonics Modulation Technologies, Inc, a medical technology company, focuses on the design, development, and commercialization of sacral neuromodulation solutions (SNM) solutions. The SNM therapy is primarily used to treat patients with overactive bladder, fecal incontinence, and urinary retention. The company was formerly known as American Restorative Medicine, Inc and changed its name to Axonics Modulation Technologies, Inc in August 2013.

Further Reading: What is an SEC Filing?

Receive News & Ratings for Axonics Modulation Technologies Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axonics Modulation Technologies Inc and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply